Form 4: West Pharmaceutical Services Director Paolo Pucci Reports Acquisition of Restricted Stock Units

Director Paolo Pucci reports the acquisition of 1,071 restricted stock units in West Pharmaceutical Services, Inc.

Summary

• Paolo Pucci, a director of West Pharmaceutical Services Inc., filed a Form 4 on May 8, 2025, reporting a transaction that occurred on May 6, 2025.
• The transaction involved the acquisition of 1,071 shares of common stock in the form of restricted stock units.
• These shares were acquired at a price of $0.
• Following the transaction, Pucci directly owns 10,946.95 shares of West Pharmaceutical Services Inc. common stock.
• The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
• Pucci has also granted a Limited Power of Attorney, effective May 16, 2024, to Luis Cantarero, Louis Lalli, Ryan Metz, and Caitlin Hippeli to execute and file Section 16(a) filings on his behalf.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Positives

• The acquisition of restricted stock units could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of restricted stock units by a director may signal confidence in the company's future, potentially impacting shareholder sentiment positively.

Next Steps

• The restricted stock units will vest at the next annual shareholder meeting.

Key Dates

Keywords

Form 4, restricted stock units, beneficial ownership, Section 16(a), West Pharmaceutical Services, Paolo Pucci, director, WST